Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 5972-5983

  Zhang, Libo ^a,b   Marrano, Paula ^b   Kumar, Sushil ^d   Leadley, Michael ^b   Elias, Evelyn ^b   Thorner, Paul ^b,d   Baruchel, Sylvain ^a,c,d  

^a Division of Haematology/Oncology   (Canada)

^b Department of Paediatric Laboratory Medicine ^*  (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CASPASE 3; DOCETAXEL; HISTONE H3; NANOPARTICLE; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL STRAIN; CELL STRAIN CHLA 20; CELL STRAIN RD; CELL STRAIN RH4; CELL STRAIN SK N BE; CELL VIABILITY; CHILDHOOD CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; DRUG STABILITY; DRUG TUMOR LEVEL; FEMALE; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; METASTASIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RHABDOMYOSARCOMA; SARCOMA CELL; SOLID TUMOR; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; NEOPLASMS; NEUROBLASTOMA; OSTEOSARCOMA; PACLITAXEL; RHABDOMYOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887124322     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1485     Document Type: Article

References (44)

1. Coppes MJ, Dome JS. Pediatric Clinics of North America: pediatric oncology. Preface Pediatr Clin North Am 2008;55:xv-xvi.
2. Davenport KP, Blanco FC, Sandler AD. Pediatric malignancies: neuroblastoma, Wilm's tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. Surg Clin North Am 2012;92: 745-67.
3. Pappo AS, Shapiro DN, Crist WM. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 1997;44: 953-72.
4. Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep 2010;12: 402-10.
5. Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 2008;26: 406-13.
6. McCarville MB, Spunt SL, Pappo AS. Rhabdomyosarcoma in pediatric patients: the good, the bad, and the unusual. AJR Am J Roentgenol 2001;176: 1563-9.
7. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37: 286-302.
8. Mugishima H. Current status of molecular biology and treatment strategy for neuroblastoma. Int J Clin Oncol 2012;17: 189.
9. Ora I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 2011;21: 217-28.
10. Horwitz SB, Lothstein L, Manfredi JJ, Mellado W, Parness J, Roy SN, et al. Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 1986;466: 733-44.
11. Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990;248: 370-2.
12. Carboni JM, Singh C, Tepper MA. Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins. J Natl Cancer Inst Monogr 1993:(15) 95-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=Taxol+and +lipopolysaccharide+activation+of+a+murine+macrophage+cell +line+and+induction+of+similar+tyrosine+phosphoproteins.
13. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 1997;94: 9679-83.
14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277: 665-7.
15. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20: 1-15.
16. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004;90: 304-5.
17. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90: 300-6.
18. Vassal G, Terrier-Lacombe MJ, Bissery MC, Venuat AM, Gyergyay F, Benard J, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996;74: 537-45.
19. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 2001;84: 604-10.
20. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML. Phase 1 study of paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 2003;25: 539-42.
21. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, et al. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol 2001;23: 277-81.
22. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 2004;22: 4119-26.
23. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8: 1038-44.
24. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor- free, nanoparticle albumin-bound paclitaxel (ABI-007), and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11: 4136-43.
25. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12: 1317-24.
26. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235: 179-92.
27. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3: 755-66.
28. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23: 7785-93.
29. O'Shaughnessy J TS, Davidson N, et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus taxol in MBC: a phase III trial [abstract]. In: Proceedings from the 26th Annual San Antonio Breast Cancer Symposium; 2003; San Antonio, TX: 2003. Abstract No. 44, p. 182. San Antonio, Texas.
30. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 2005;1: 755-62.
31. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7: 1041-53.
32. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46: 6387-92.
33. Duncan JP, Pameijer CH. Retention of parallel-sided titanium posts cemented with six luting agents: an in vitro study. J Prosthet Dent 1998;80: 423-8.
34. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59: 1454-7.
35. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42: 665-85.
36. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013;497: 633-7.
37. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298: 1236-42.
38. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant betatubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272: 17118-25.
39. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3: 1-19.
40. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002;17: 234-42.
41. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999;5: 3445-53.
42. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005;55: 277-85.
43. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53: 615-27.
44. Colin de Verdiere A, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 1994;33: 504-8.